Patents Represented by Attorney Richard Aron Osman
  • Patent number: 8334311
    Abstract: Indoline compounds having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders are provided.
    Type: Grant
    Filed: July 25, 2011
    Date of Patent: December 18, 2012
    Assignee: Joyant Pharmaceuticals, Inc.
    Inventors: Gunnar James Hanson, Qi Wei, Charles Caldwell, Ming Zhou, Lai Wang, Susan Harran
  • Patent number: 8329745
    Abstract: Ghrelin O-acyltransferase (GOAT) is inhibited with designed small molecules of the general formula: Methods comprise contacting the GOAT with an inhibitor and detecting a resultant inhibition.
    Type: Grant
    Filed: September 6, 2011
    Date of Patent: December 11, 2012
    Assignee: Board of Regents, The University of Texas System
    Inventors: Patrcik G. Harran, Michael S. Brown, Joseph L. Goldstein, Jing Yang, Tong-Jin Zhao
  • Patent number: 8324614
    Abstract: The disclosure provides methods, materials, and devices suitable for use in electroluminescent devices. In one embodiment, for example, there is provided a layered cathode comprising a metal substrate and an intermediate organic or organometallic layer having an electron accepting group. The intermediate layer provides an interface with an overlaying electroluminescent layer. The disclosure finds utility, for example, in the field of microelectronic devices.
    Type: Grant
    Filed: August 25, 2008
    Date of Patent: December 4, 2012
    Assignee: SRI International
    Inventor: Yijian Shi
  • Patent number: 8299268
    Abstract: This invention relates to novel macrocyclic lactams intermediates useful for the preparation of diazonamide analogs. This invention also relates to a novel electrochemical oxidative cyclization for the preparation of such macrocyclic lactams, and their further elucidation to provide diazonamide analogs.
    Type: Grant
    Filed: July 19, 2011
    Date of Patent: October 30, 2012
    Assignees: Board of Regents, The University of Texas System, Joyant Pharmaceuticals, Inc.
    Inventors: Gunnar Hanson, Charles Caldwell, Patrick G. Harran, Susan Harran, Qi Wei, Ming Zhou
  • Patent number: 8293339
    Abstract: The invention provides methods and apparatuses for making an artificial, amphiphilic bilayer using aqueous micro-droplets (1-1,000 um dia) in a water-immiscible solvent, wherein immediately surrounding each droplet is a monolayer of amphiphilic molecules; the general method comprising: juxtapositioning the droplets with a focused laser beam such that the monolayers merge to create a bilayer of the amphiphilic molecules between the droplets.
    Type: Grant
    Filed: September 17, 2008
    Date of Patent: October 23, 2012
    Assignee: SRI International, Inc.
    Inventors: Gregory W. Faris, Sanhita Dixit
  • Patent number: 8288158
    Abstract: A mammalian cell comprising a recombinant, functional L-threonine 3-dehydrogenase (EC 1.1.1.103; TDH) gene, methods of making, and methods of use.
    Type: Grant
    Filed: June 12, 2009
    Date of Patent: October 16, 2012
    Assignee: Board of Regents, The University of Texas System
    Inventors: Steven L. McKnight, Jian Wang
  • Patent number: 8278341
    Abstract: Compounds useful as antibacterial agents are provided. The compounds are analogs of indole-3-carbinol and have a backbone selected from dihydroindolo[2,3-b]carbazole, 2,2?-diindolylmethane, 2?,3-diindolylmethane, and 3,3?-diindolylmethane. The compounds are useful therapeutic and prophylactic treatment of bacterial infections in mammals. Methods of synthesis of the compounds are provided, as are pharmaceutical compositions containing the compounds.
    Type: Grant
    Filed: September 17, 2009
    Date of Patent: October 2, 2012
    Assignee: SRI International
    Inventors: Ling Jong, Faming Jiang, Gaoquan Li, Kristien Mortelmans
  • Patent number: 8268807
    Abstract: The disclosure provides compositions and methods for treating multiple myeloma. In some embodiments, the compositions comprise (E)-3-hydroxy-21-[2?-(N,N-dimethylamino)ethoxy]-19-norpregna-1,3,5(10),17(20)-tetraene or a pharmaceutically acceptable salt or prodrug thereof and a pharmaceutical carrier.
    Type: Grant
    Filed: April 18, 2011
    Date of Patent: September 18, 2012
    Assignee: SRI International
    Inventors: Wan-Ru Chao, Nathan Collins, Lidia Sambucetti, Dominic Dinh
  • Patent number: 8258163
    Abstract: Methods and compositions for agonizing a type-2 orexin receptor (OX2R) in a cell determined to be in need thereof, including the general method of (a) administering to a subject a cyclic guanidinyl OX2R agonist and (b) detecting a resultant enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: September 4, 2012
    Assignee: Board of Regents, The University of Texas System
    Inventor: Masashi Yanagisawa
  • Patent number: 8222291
    Abstract: The invention provides small molecule mimics of the Smac peptide that are dimer- or dimer-like compounds having two amide-containing domains connected by a linker. These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including cancer and autoimmune disorders.
    Type: Grant
    Filed: October 4, 2010
    Date of Patent: July 17, 2012
    Assignee: Joyant Pharmaceuticals, Inc.
    Inventors: Gunnar J. Hanson, David Thomas, Nizal Chandrakumar, Susan Harran
  • Patent number: 8197507
    Abstract: Tissue lacerations are closed using a vacuum cup applied to the tissue surface having a tissue-abutting, optically transparent mesh surface that under vacuum conforms with the tissue surface, apposing edges of the wound, and is optionally loaded with a bandage comprising a chitosan film and a collagen backing. An eye tissue surface wound is closed without sutures by closing the wound with a bioadhesive, biocompatible sclera or cornea wound patch comprising a chitosan film and a collagen backing, wherein the backing is bonded to the film without adhesive and protects the film against dissociation when the patch is exposed to a physiological fluid, and the film adheres to the sclera sufficient to retain apposed edges of the wound.
    Type: Grant
    Filed: January 14, 2009
    Date of Patent: June 12, 2012
    Assignee: SRI International
    Inventors: Pablo E. Garcia, Bryan Chavez, Jomayon Hill
  • Patent number: 8172967
    Abstract: A solvent-free process is used to make moldable plastic explosives or moldable plastic explosive simulant products.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: May 8, 2012
    Assignee: Kemzecur, Inc.
    Inventors: Albert Wartman, Bruce Barak Koffler
  • Patent number: 8153619
    Abstract: Novel diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders are provided.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: April 10, 2012
    Assignee: Joyant Pharmaceuticals, Inc.
    Inventors: Gunnar James Hanson, Ming Zhou, Qi Wei, Charles Caldwell
  • Patent number: 8143418
    Abstract: Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-L-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and a resultant increase in apoptosis of the target cells is detected. The contacting step may be effected by administering to a pharmaceutical composition comprising a therapeutically effective amount of The compoundic mimetic, wherein the individual may be subject to concurrent or antecedent radiation or chemotherapy for treatment of a neoproliferative pathology.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: March 27, 2012
    Assignee: Board of Regents, The University of Texas System
    Inventors: Patrick G. Harran, Xiaodong Wang, Jef K. De Brabander, Lin Li, Ranny Mathew Thomas, Hidetaka Suzuki
  • Patent number: 8110404
    Abstract: Lanthanide chelates derived from diazacrown ethers having two ethyliminodiacetic acid side chains have increased ability to bind lanthanide ions.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: February 7, 2012
    Assignee: Board of Trustees of the University of Illinois
    Inventors: Paul R. Selvin, Pinghua Ge
  • Patent number: 8026093
    Abstract: Specially modified microbial growth surfaces improve bacterial recovery or counts when testing for the presence or absence of microbial cells or performing microbial enumerations.
    Type: Grant
    Filed: November 10, 2008
    Date of Patent: September 27, 2011
    Assignee: The Regents of the University of California
    Inventors: Rosalind Tung, George W. Chang
  • Patent number: 8013015
    Abstract: Ghrelin O-acyltransferase (GOAT) is inhibited with designed small molecules. Methods comprise contacting the GOAT with an inhibitor and detecting a resultant inhibition.
    Type: Grant
    Filed: October 1, 2009
    Date of Patent: September 6, 2011
    Assignee: Board of Regents, The University of Texas System
    Inventors: Patrcik G. Harran, Michael S. Brown, Joseph L. Goldstein, Jing Yang, Tong-Jin Zhao
  • Patent number: 8014953
    Abstract: Computational methods for systematically characterizing putative protein isoforms as apparent targets of nonsense-mediated decay (NMD) comprise: (a) identifying a dataset of target putative protein isoform sequences for characterization; (b) identifying from an mRNA dataset corresponding mRNA sequences representing transcripts encoding the protein isoforms; (c) determining corresponding gene intron-exon structures by mapping the mRNA sequences to corresponding genomic sequences; and (d) determining if the transcripts are apparent targets of NMD. Methods for regulating the expression of a gene encoding a protein isoform characterized as an apparent target of NMD comprise biasing expression of the isoform by modulating transcript splicing or modulating NMD activity.
    Type: Grant
    Filed: August 8, 2003
    Date of Patent: September 6, 2011
    Assignee: The Regents of the University of California
    Inventors: Steven E. Brenner, Richard E. Green, R. Tyler Hillman
  • Patent number: 7989502
    Abstract: Modafinil is selectively delivered to the brain, minimizing delivery to the blood, of a person in need thereof by administering to the person a therapeutically-effective dosage of modafinil, wherein the dosage is less than 1 mg, formulated in a lipid microemulsion (LME) and selectively delivered to the upper third of the nasal cavity. The method may be implemented with an intranasal pharmaceutical delivery device loaded with a modafinil composition and adapted to deliver the dosage to the upper third of the nasal cavity.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: August 2, 2011
    Assignees: SRI International, HealthPartners Research Foundation
    Inventors: Mary Ann Katherine Greco, William Howard Frey, II, Jacqueline DeRose, Rachel Beth Matthews, Leah Ranae Bresin Hanson
  • Patent number: RE42748
    Abstract: A composition for oral radionuclide chelation therapy comprises a DTPA chelate selected from Zn-DTPA and Ca-DTPA and a permeation enhancer that preferentially increases jejunal uptake of the DTPA chelate. The composition has a DTPA chelate bioavailability of at least 10% of the chelate when orally administered to a mammal.
    Type: Grant
    Filed: April 17, 2011
    Date of Patent: September 27, 2011
    Assignee: SRI International
    Inventors: Gita Natarajan Shankar, Helen Jaber Parish